Distinct mechanisms of axonal globule formation in mice expressing human wild type α-synuclein or dementia with Lewy bodies-linked P123H ß-synuclein

Molecular Brain

Volumn 5, Issue 1, 2012, Pages

  Sekigawa, Akio ^a   Fujita, Masayo ^a   Sekiyama, Kazunari ^a   Takamatsu, Yoshiki ^a   Hatano, Taku ^b   Rockenstein, Edward ^c   La Spada, Albert R ^d,e   Masliah, Eliezer ^c   Hashimoto, Makoto ^a  

^a TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

synuclein; Lysosome; Mitochondria; P123H synuclein; Parkinson's disease; Transgenic mouse

Indexed keywords

4 HYDROXYNONENAL; ALPHA SYNUCLEIN; BETA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2;

AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGOSOME; BASAL GANGLION; BRAIN REGION; DIFFUSE LEWY BODY DISEASE; IMMUNOREACTIVITY; LYSOSOME; MITOCHONDRION; MOUSE; NERVE FIBER; NERVE FIBER DEGENERATION; NITRATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN STRUCTURE; THALAMUS; TRANSGENIC MOUSE; WILD TYPE;

AGING; ALPHA-SYNUCLEIN; ANIMALS; AXONS; BETA-SYNUCLEIN; BRAIN; DEMENTIA; HUMANS; LEWY BODY DISEASE; LYSOSOMES; MICE; MICE, TRANSGENIC; MITOCHONDRIA; MUTANT PROTEINS; OXIDATIVE STRESS; PARKINSON DISEASE; RISK FACTORS;

MUS; MUS MUSCULUS;

EID: 84866547908     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-5-34     Document Type: Article

References (40)

1. Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia. Trojanowski JQ, Goedert M, Iwatsubo T, Lee VM, Cell Death Differ 1998 5 832 837 10.1038/sj.cdd.4400432 10203692 (Pubitemid 28484393)
2. Alpha-synuclein in Lewy body disease and Alzheimer's disease. Hashimoto M, Masliah E, Brain Pathol 1999 9 707 720 10517509 (Pubitemid 29470963)
3. Stages in the development of Parkinson's disease-related pathology. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K, Cell Tissue Res 2004 318 121 134 10.1007/s00441-004-0956-9 15338272 (Pubitemid 39362633)
4. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Braak H, de Vos RA, Bohl J, Del Tredici K, Neurosci Lett 2006 396 67 72 10.1016/j.neulet.2005.11.012 16330147 (Pubitemid 43233790)
5. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabayashi K, Takahashi H, Brain 2008 131 642 650 10.1093/brain/awm302 18079166 (Pubitemid 351294710)
6. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L, Science 2000 287 1265 1269 10.1126/science.287.5456.1265 10678833 (Pubitemid 30112148)
7. Neuropathology in mice expressing human alpha-synuclein. van der Putten H, Wiederhold KH, Probst A, Barbieri S, Mistl C, Danner S, Kauffmann S, Hofele K, Spooren WP, Ruegg MA, et al. The Journal of neuroscience: the official journal of the Society for Neuroscience 2000 20 6021 6029 (Pubitemid 30658395)
8. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM, Neuron 2002 34 521 533 10.1016/S0896-6273(02)00682-7 12062037 (Pubitemid 34628750)
9. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53-> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL, Proc Natl Acad Sci USA 2002 99 8968 8973 10.1073/pnas.132197599 12084935 (Pubitemid 34693667)
10. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. Galvin JE, Uryu K, Lee VM, Trojanowski JQ, Proc Natl Acad Sci USA 1999 96 13450 13455 10.1073/pnas.96.23. 13450 10557341
11. Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology. Galvin JE, Giasson B, Hurtig HI, Lee VM, Trojanowski JQ, Am J Pathol 2000 157 361 368 10.1016/S0002-9440(10)64548-8 10934140 (Pubitemid 30626903)
12. β-synuclein in the pathogenesis of Parkinson's disease and related α-synucleinopathies: emerging roles and new directions. Hashimoto M, La Spada AR, Future Neurology 2012 7 155 163 10.2217/fnl.12.5
13. Heterogeneity of nigral and cortical Lewy bodies differentiated by amplified triple-labeling for alpha-synuclein, ubiquitin, and thiazin red. Sakamoto M, Uchihara T, Hayashi M, Nakamura A, Kikuchi E, Mizutani T, Mizusawa H, Hirai S, Exp Neurol 2002 177 88 94 10.1006/exnr.2002.7961 12429213 (Pubitemid 35356824)
14. Pale neurites, premature alpha-synuclein aggregates with centripetal extension from axon collaterals. Kanazawa T, Adachi E, Orimo S, Nakamura A, Mizusawa H, Uchihara T, Brain Pathol 2012 22 67 78 10.1111/j.1750-3639.2011. 00509.x 21672073
15. A beta-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain. Fujita M, Sugama S, Sekiyama K, Sekigawa A, Tsukui T, Nakai M, Waragai M, Takenouchi T, Takamatsu Y, Wei J, et al. Nat Commun 2010 1 110 10.1038/ncomms1101 21045828
16. A case of adult neuronal ceroid-lipofuscinosis with the appearance of membranous cytoplasmic bodies localized in the spinal anterior horn. Iseki E, Amano N, Yokoi S, Yamada Y, Suzuki K, Yazaki M, Acta Neuropathol 1987 72 362 368 10.1007/BF00687268 3033977 (Pubitemid 17024309)
17. Deposits of neuronal ceroid-lipofuscinosis in transitional structures-electron microscopic study. Kurokawa Y, Ueno T, Nakamura N, Kimura N, Folia Psychiatr Neurol Jpn 1985 39 537 542 3833632 (Pubitemid 16161085)
18. Differential distribution of major gangliosides in rat central nervous system detected by specific monoclonal antibodies. Kotani M, Kawashima I, Ozawa H, Terashima T, Tai T, Glycobiology 1993 3 137 146 10.1093/glycob/3.2.137 8490240 (Pubitemid 23132604)
19. Immunohistochemical localization of minor gangliosides in the rat central nervous system. Kotani M, Kawashima I, Ozawa H, Ogura K, Ishizuka I, Terashima T, Tai T, Glycobiology 1994 4 855 865 10.1093/glycob/4.6.855 7734848
20. Outer membrane VDAC1 controls permeability transition of the inner mitochondrial membrane in cellulo during stress-induced apoptosis. Tomasello F, Messina A, Lartigue L, Schembri L, Medina C, Reina S, Thoraval D, Crouzet M, Ichas F, De Pinto V, De Giorgi F, Cell Res 2009 19 1363 1376 10.1038/cr.2009.98 19668262
21. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, et al. Nat Genet 2006 38 515 517 10.1038/ng1769 16604074
22. Reverse of age-dependent memory impairment and mitochondrial DNA damage in microglia by an overexpression of human mitochondrial transcription factor a in mice. Hayashi Y, Yoshida M, Yamato M, Ide T, Wu Z, Ochi-Shindou M, Kanki T, Kang D, Sunagawa K, Tsutsui H, Nakanishi H, The Journal of neuroscience: the official journal of the Society for Neuroscience 2008 28 8624 8634 10.1523/JNEUROSCI.1957-08.2008
23. Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. Ubhi K, Lee PH, Adame A, Inglis C, Mante M, Rockenstein E, Stefanova N, Wenning GK, Masliah E, J Neurosci Res 2009 87 2728 2739 10.1002/jnr.22089 19405128
24. Parkinson's disease: a genetic perspective. Belin AC, Westerlund M, FEBS J 2008 275 1377 1383 10.1111/j.1742-4658.2008.06301.x 18279377 (Pubitemid 351388789)
25. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, et al. Nat Genet 2009 41 1303 1307 10.1038/ng.485 19915576
26. LRRK2 regulates synaptic vesicle endocytosis. Shin N, Jeong H, Kwon J, Heo HY, Kwon JJ, Yun HJ, Kim CH, Han BS, Tong Y, Shen J, et al. Exp Cell Res 2008 314 2055 2065 10.1016/j.yexcr.2008.02.015 18445495
27. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, Yu SW, Savitt JM, Waldvogel HJ, et al. Ann Neurol 2006 60 557 569 10.1002/ana.21019 17120249 (Pubitemid 44871798)
28. Biochemical and pathological characterization of Lrrk2. Giasson BI, Covy JP, Bonini NM, Hurtig HI, Farrer MJ, Trojanowski JQ, Van Deerlin VM, Ann Neurol 2006 59 315 322 10.1002/ana.20791 16437584 (Pubitemid 43202485)
29. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Melrose HL, Kent CB, Taylor JP, Dachsel JC, Hinkle KM, Lincoln SJ, Mok SS, Culvenor JG, Masters CL, Tyndall GM, et al. Neuroscience 2007 147 1047 1058 10.1016/j.neuroscience.2007.05.027 17611037 (Pubitemid 47102551)
30. Monitoring autophagy in Alzheimer's disease and related neurodegenerative diseases. Yang DS, Lee JH, Nixon RA, Methods Enzymol 2009 453 111 144 19216904
31. Autophagy in dementias. Kragh CL, Ubhi K, Wyss-Corey T, Masliah E, Brain Pathol 2012 22 99 109 10.1111/j.1750-3639.2011.00545.x 22150925
32. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, Lee MK, The Journal of neuroscience: the official journal of the Society for Neuroscience 2006 26 41 50 10.1523/JNEUROSCI.4308-05.2006 (Pubitemid 43089519)
33. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Bosco DA, Fowler DM, Zhang Q, Nieva J, Powers ET, Wentworth P Jr, Lerner RA, Kelly JW, Nat Chem Biol 2006 2 249 253 16565714
34. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A, Neuron 2006 52 587 593 10.1016/j.neuron.2006.10.008 17114044 (Pubitemid 44781171)
35. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Li Y, Liu W, Oo TF, Wang L, Tang Y, Jackson-Lewis V, Zhou C, Geghman K, Bogdanov M, Przedborski S, et al. Nat Neurosci 2009 12 826 828 10.1038/nn.2349 19503083
36. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Lin X, Parisiadou L, Gu XL, Wang L, Shim H, Sun L, Xie C, Long CX, Yang WJ, Ding J, et al. Neuron 2009 64 807 827 10.1016/j.neuron.2009.11.006 20064389
37. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E, J Neurosci Res 2002 68 568 578 10.1002/jnr.10231 12111846 (Pubitemid 34575622)
38. Important factors for the three-dimensional reconstruction of neuronal structures from serial ultrathin sections. Kubota Y, Hatada SN, Kawaguchi Y, Frontiers in Neural Circuits 2009 3 4 19521546
39. Immunocytochemical localization of prolactin-releasing peptide in the rat brain. Maruyama M, Matsumoto H, Fujiwara K, Kitada C, Hinuma S, Onda H, Fujino M, Inoue K, Endocrinology 1999 140 2326 2333 10.1210/en.140.5.2326 10218986 (Pubitemid 30636474)
40. Eine Methode des mikrochemischen Cholesterinnachweises am Gewebsschnitt. Schultz A, Zentralblatt fur Allgemeine pathologie und Pathologische Anatomie 1924 35 314 317